BACKGROUND: Enteric fever in the United States has been primarily associated with travel and with worrisome changes in global patterns of antimicrobial resistance. We present the first comprehensive report of National Typhoid and Paratyphoid Fever Surveillance System (NTPFS) data for a 5-year period (2008-2012). METHODS: We reviewed data on laboratory-confirmed cases reported to NTPFS, and related antimicrobial susceptibility results of Salmonella Typhi and Paratyphi A isolates sent for testing by participating public health laboratories to the Centers for Disease Control and Prevention's National Antimicrobial Resistance Monitoring System laboratory. RESULTS: During 2008-2012, 2341 enteric fever cases were reported, 80% typhoid and 20% paratyphoid A. The proportion caused by paratyphoid A increased from 16% (2008) to 22% (2012). Foreign travel within 30 days preceding illness onset was reported by 1961 (86%) patients (86% typhoid and 92% paratyphoid A). Travel to southern Asia was common (82% for typhoid, 97% for paratyphoid A). Among 1091 (58%) typhoid and 262 (56%) paratyphoid A isolates tested for antimicrobial susceptibility, the proportion resistant to nalidixic acid (NAL-R) increased from 2008 to 2012 (Typhi, 60% to 68%; Paratyphi A, 91% to 94%). Almost all NAL-R isolates were resistant or showed decreased susceptibility to ciprofloxacin. Resistance to at least ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole (multidrug resistant [MDR]) was limited to Typhi isolates, primarily acquired in southern Asia (13%). Most MDR isolates were also NAL-R. CONCLUSIONS: Enteric fever in the United States is primarily associated with travel to southern Asia, and increasing resistance is adding to treatment challenges. A bivalent typhoid and paratyphoid vaccine is needed. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND:Enteric fever in the United States has been primarily associated with travel and with worrisome changes in global patterns of antimicrobial resistance. We present the first comprehensive report of National Typhoid and Paratyphoid Fever Surveillance System (NTPFS) data for a 5-year period (2008-2012). METHODS: We reviewed data on laboratory-confirmed cases reported to NTPFS, and related antimicrobial susceptibility results of Salmonella Typhi and Paratyphi A isolates sent for testing by participating public health laboratories to the Centers for Disease Control and Prevention's National Antimicrobial Resistance Monitoring System laboratory. RESULTS: During 2008-2012, 2341 enteric fever cases were reported, 80% typhoid and 20% paratyphoid A. The proportion caused by paratyphoid A increased from 16% (2008) to 22% (2012). Foreign travel within 30 days preceding illness onset was reported by 1961 (86%) patients (86% typhoid and 92% paratyphoid A). Travel to southern Asia was common (82% for typhoid, 97% for paratyphoid A). Among 1091 (58%) typhoid and 262 (56%) paratyphoid A isolates tested for antimicrobial susceptibility, the proportion resistant to nalidixic acid (NAL-R) increased from 2008 to 2012 (Typhi, 60% to 68%; Paratyphi A, 91% to 94%). Almost all NAL-R isolates were resistant or showed decreased susceptibility to ciprofloxacin. Resistance to at least ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole (multidrug resistant [MDR]) was limited to Typhi isolates, primarily acquired in southern Asia (13%). Most MDR isolates were also NAL-R. CONCLUSIONS:Enteric fever in the United States is primarily associated with travel to southern Asia, and increasing resistance is adding to treatment challenges. A bivalent typhoid and paratyphoid vaccine is needed. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: S J Olsen; S C Bleasdale; A R Magnano; C Landrigan; B H Holland; R V Tauxe; E D Mintz; S Luby Journal: Epidemiol Infect Date: 2003-02 Impact factor: 2.451
Authors: Regina C LaRocque; Bhushan R Deshpande; Sowmya R Rao; Gary W Brunette; Mark J Sotir; Emily S Jentes; Edward T Ryan Journal: Am J Trop Med Hyg Date: 2012-11-13 Impact factor: 2.345
Authors: A Duncan Steele; Deborah C Hay Burgess; Zoey Diaz; Megan E Carey; Anita K M Zaidi Journal: Clin Infect Dis Date: 2016-03-15 Impact factor: 9.079
Authors: Andi L Shane; Rajal K Mody; John A Crump; Phillip I Tarr; Theodore S Steiner; Karen Kotloff; Joanne M Langley; Christine Wanke; Cirle Alcantara Warren; Allen C Cheng; Joseph Cantey; Larry K Pickering Journal: Clin Infect Dis Date: 2017-11-29 Impact factor: 9.079
Authors: Stefan H F Hagmann; Kristina M Angelo; Ralph Huits; Katherine Plewes; Gilles Eperon; Martin P Grobusch; Anne McCarthy; Michael Libman; Eric Caumes; Daniel T Leung; Hilmir Asgeirsson; Mogens Jensenius; Eli Schwartz; Adrian Sánchez-Montalvá; Paul Kelly; Prativa Pandey; Karin Leder; Daniel L Bourque; Yukihiro Yoshimura; Frank P Mockenhaupt; Perry J J van Genderen; Silvia Odolini; Patricia Schlagenhauf; Bradley A Connor; Davidson H Hamer Journal: Antimicrob Agents Chemother Date: 2020-10-20 Impact factor: 5.191
Authors: Michael Marks; Margaret Armstrong; Christopher J M Whitty; Justin F Doherty Journal: Trans R Soc Trop Med Hyg Date: 2016-09-12 Impact factor: 2.184
Authors: Amruta Radhakrishnan; Daina Als; Eric D Mintz; John A Crump; Jefferey Stanaway; Robert F Breiman; Zulfiqar A Bhutta Journal: Am J Trop Med Hyg Date: 2018-07-24 Impact factor: 2.345